➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Boehringer Ingelheim
Colorcon
Merck

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

ZYRTEC ALLERGY Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Zyrtec Allergy patents expire, and what generic alternatives are available?

Zyrtec Allergy is a drug marketed by J And J Consumer Inc and is included in two NDAs.

The generic ingredient in ZYRTEC ALLERGY is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and thirty-three suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

Drug patent expirations by year for ZYRTEC ALLERGY
Recent Clinical Trials for ZYRTEC ALLERGY

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare DivisionPhase 1
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Early Phase 1
Northwestern UniversityEarly Phase 1

See all ZYRTEC ALLERGY clinical trials

US Patents and Regulatory Information for ZYRTEC ALLERGY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc ZYRTEC ALLERGY cetirizine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 022578-001 Sep 3, 2010 OTC Yes Yes   Start Trial   Start Trial   Start Trial
J And J Consumer Inc ZYRTEC ALLERGY cetirizine hydrochloride TABLET;ORAL 019835-003 Nov 16, 2007 DISCN Yes No   Start Trial   Start Trial   Start Trial
J And J Consumer Inc ZYRTEC ALLERGY cetirizine hydrochloride TABLET;ORAL 019835-004 Nov 16, 2007 OTC Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ZYRTEC ALLERGY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0058146 SPC/GB01/052 United Kingdom   Start Trial SPC/GB01/052:, EXPIRES: 20070205
0663828 C300085 Netherlands   Start Trial PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146 2001C/045 Belgium   Start Trial PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Boehringer Ingelheim
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.